RxDoctor Payments Data

Sumitha Ganji, MD

Nephrology · Slidell, LANPI 1215252853

Payments from drug & device makers

$3,092in general payments, 2019–2025

Across 174 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$430
  • Amgen$402
  • Vifor Pharma, Inc.$359
  • Mallinckrodt Hospital Products Inc.$303
  • AstraZeneca$299
  • Fresenius USA Marketing, Inc.$272
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$401%
  • Food & beverage$3,05299%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,092 in reported general payments places this provider in the 55th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$197,393
Medicare patients
426
Services billed
1,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol141$133,998
FarxigaDapagliflozin Propanediol114$99,684
JardianceEmpagliflozin57$61,609
VeltassaPatiromer Calcium Sorbitex53$57,422
KerendiaFinerenone36$24,611
LokelmaSodium Zirconium Cyclosilicate32$19,247
Calcitriol493$7,312
Cinacalcet Hcl15$2,505
Allopurinol298$2,252
Potassium Chloride74$2,013
Torsemide46$1,217
Midodrine Hcl15$1,065
Hydralazine Hcl76$903
Calcium Acetate12$684
Furosemide169$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$141$133,998141 claims
AstraZenecaFarxiga, Lokelma$299$118,931146 claims
BayerKerendia$126$24,61136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →